1. Preclinical antitumor activity of XK469 (NSC 656889)

   • Patricia M LoRusso
   • Ralph Parchment
   • Thomas H. Corbett

   OriginalPaper Pages: 287 - 296

2. Effect of the cisplatin-procaine complex DPR in combination with several anticancer agents on murine P388 leukemic cells in vitro and in vivo

   • Ilaria Pastrone
   • Maurizio Viale
   • Mauro Esposito

   OriginalPaper Pages: 297 - 302

3. Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations

   • David R. Shalinsky
   • John Brekken
   • Krzysztof Appelt

   OriginalPaper Pages: 303 - 313

4. Pala Versus Streptozotocin, Doxorubicin, and Meccnu in the Treatment of Patients With Advanced Pancreatic Carcinoma

   • Robert S. Witte
   • Louise M. Ryan
   • Paul F. Engstrom

   OriginalPaper Pages: 315 - 318

5. Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion

   • I. Rassmann
   • R. Thödtmann
   • A.-R. Hanauske

   OriginalPaper Pages: 319 - 324

6. A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors

   • Jordan D. Berlin
   • Dona B. Alberti
   • George Wilding

   OriginalPaper Pages: 325 - 330

7. Phase II study of Didemnin B in central nervous system tumors: A Southwest Oncology Group study

   • Sarah A. Taylor
   • Dorothy J. Giroux
   • S. Clifford Schold

   OriginalPaper Pages: 331 - 332

8. Oral etoposide for patients with advanced adenocarcinoma of the pancreas

   • Eva Thomas
   • Pamela Dumas
   • Jaffer A. Ajani

   OriginalPaper Pages: 333 - 335

9. A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma

   • William J. Berg
   • John McCaffrey
   • Robert J. Motzer

   OriginalPaper Pages: 337 - 340

10. Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hour continuous infusion weekly for three weeks in metastatic colorectal carcinoma

    • Richard Pazdur
    • Diana C. Medgyesy
    • James L. Abbruzzese

    OriginalPaper Pages: 341 - 346

11. Phase II trial of edatrexate in relapsed or refractory germ cell tumors: A Southwest Oncology Group study (SWOG 9124)

    • Frederick J. Meyers
    • Danika Lew
    • E. David Crawford

    OriginalPaper Pages: 347 - 351

12. A phase II trial of irinotecan in hormone-refractory prostate cancer

    • David M. Reese
    • Simon Tchekmedyian
    • Peter J. Rosen

    OriginalPaper Pages: 353 - 359

13. Contents Volume 16, 1998

    OriginalPaper Pages: 361 - 366

14. Instructions for authors

    OriginalPaper Pages: 367 - 368